| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | −$830,0611 | −$130,1672 | −$125,5263 | −$68,3454 | −$56,1824 |
| Operating cash flow | −$206,8315 | −$38,4806 | −$66,3897 | −$4,4338 | −$47,9798 |
| Capital expenditure | — | — | — | — | — |
| Free cash flow (derived) | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $11,6759 | $73,19510 | $6,80611 | $2,37311 | $66112 |
| Diluted shares | 73.4M | 80.0M | 81.7M | 83.5M | 83.5M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom). A derived or summed figure cites every filing line it was built from.
10 shares is a claim on −$0.03 of net worth that earned you −$0.01 last year.
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Share count is up 14% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
This page is free, and so is every other company on MeritValue.
Connect the MeritValue MCP server to Claude or another MCP client, ask about Nu-Med Plus, Inc., and get these exact figures with their filing receipts — not an improvised DCF.
Get a free key →Pull the companies with a published value under any model (up to 500 a request, filtered by data completeness) into your own sheet or agent. Screening is what Analyst adds, at $9/month.
See pricing →Follow NUMD and keep your own price beside the value. The same engine, with the same receipts.
MeritValue on the App Store →- 10-K/A filed 2023-04-03 · period ending 2021-12-31 · accession 0001548123-23-000068 (NetIncomeLoss)
- 10-K filed 2024-03-26 · period ending 2022-12-31 · accession 0001548123-24-000025 (NetIncomeLoss)
- 10-K filed 2025-03-31 · period ending 2023-12-31 · accession 0001548123-25-000021 (NetIncomeLoss)
- 10-K filed 2026-04-15 · periods ending 2024-12-31, 2025-12-31 · accession 0001543637-26-000005 (NetIncomeLoss)
- 10-K/A filed 2023-04-03 · period ending 2021-12-31 · accession 0001548123-23-000068 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2024-03-26 · period ending 2022-12-31 · accession 0001548123-24-000025 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2025-03-31 · period ending 2023-12-31 · accession 0001548123-25-000021 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2026-04-15 · periods ending 2024-12-31, 2025-12-31 · accession 0001543637-26-000005 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2024-03-26 · period ending 2021-12-31 · accession 0001548123-24-000025 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
- 10-K filed 2025-03-31 · period ending 2022-12-31 · accession 0001548123-25-000021 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
- 10-K filed 2025-03-31 · periods ending 2023-12-31, 2024-12-31 · accession 0001548123-25-000021 (CashAndCashEquivalentsAtCarryingValue)
- 10-K filed 2026-04-15 · period ending 2025-12-31 · accession 0001543637-26-000005 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)